ADMA Biologics (ADMA) CEO trades stock under Rule 10b5-1 plan

Rhea-AI Filing Summary

ADMA Biologics’ president and CEO reported option exercises and stock sales in company shares. On 12/15/2025, he exercised a stock option covering 15,000 shares of common stock at an exercise price of $5.40 per share and, on the same date, sold 15,000 shares and a separate 6,000-share block at a sale price of $19.79 per share. The transactions were carried out under a Rule 10b5-1 trading plan entered into on December 5, 2024 with Fidelity Brokerage Services LLC. Following these trades, he directly holds 2,007,850 shares of ADMA Biologics common stock, along with indirect holdings of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, and continues to hold 720,950 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman Adam S

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		M		15,000(1)	A	$5.4	2,028,850	D
Common Stock	12/15/2025		S		15,000(1)	D	$19.79(2)	2,013,850	D
Common Stock	12/15/2025		S		6,000(1)	D	$19.79(2)	2,007,850(3)(4)(5)	D
Common Stock								1,143,426	I	See Footnote(6)
Common Stock								580,957	I	See Footnote(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.4	12/15/2025		M			15,000(1)	(8)	02/26/2034	Common Stock	15,000	$0	720,950	D

Explanation of Responses:

1. Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

2. The price reported in Column 4 is the price at which the shares were sold.

3. Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

4. (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

5. (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 975,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

6. These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.

7. These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.

8. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

	/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did ADMA Biologics (ADMA) report in this filing?

The filing reports that ADMA Biologics’ president and CEO exercised a stock option for 15,000 shares of common stock at an exercise price of $5.40 per share on 12/15/2025 and sold 15,000 shares and a separate block of 6,000 shares of common stock at a sale price of $19.79 per share on the same date.

Were the ADMA Biologics (ADMA) insider trades made under a Rule 10b5-1 plan?

Yes. A checkbox on the form indicates the trades were made pursuant to a Rule 10b5-1 contract, and a footnote explains that the transactions were effected under a Rule 10b5-1 trading plan entered into with Fidelity Brokerage Services LLC on December 5, 2024.

How many ADMA Biologics (ADMA) shares does the CEO own directly after these transactions?

After the reported option exercise and stock sales, the president and CEO is shown as directly owning 2,007,850 shares of ADMA Biologics common stock.

What indirect holdings in ADMA Biologics (ADMA) does the reporting person have?

The form reports indirect ownership of 1,143,426 shares of common stock through Areth, LLC, where the reporting person is a control person, and 580,957 shares through Hariden, LLC, where he is the managing member.

What stock options and equity awards related to ADMA Biologics (ADMA) are described?

The filing shows a stock option with an exercise price of $5.40 per share, of which 15,000 shares were exercised on 12/15/2025 and that expires on 02/26/2034. After the transaction, the reporting person beneficially owns 720,950 derivative securities (stock options). Footnotes also describe several grants of unvested restricted stock units (RSUs) that vest over four-year periods, subject to continued service.

What is the reporting person’s role at ADMA Biologics (ADMA)?

The reporting person is identified as both a Director and an Officer of ADMA Biologics, serving as President and CEO.